- November 22, 2026
- Updated 8:04 am
FDA Nominee Commits to Mifepristone Safety Study
First on Fox: Dr. Heidi Overton, the nominee for FDA commissioner, has pledged to implement a structured timeline and specific guidelines for a safety study focused on mifepristone, a medication used for abortions. This confirmation comes from Senator Josh Hawley’s office, as reported by Fox News Digital.
Hawley, a member of the Senate Health, Education, Labor, and Pensions (HELP) Committee, has been advocating for transparency from federal health officials regarding delays in evaluating mifepristone’s safety. He stated, “These are major pro-life wins that ensure a comprehensive study and possible reinstatement of safeguards on the abortion drug removed by President Biden.” Hawley emphasized his expectation for the FDA to adhere to these commitments. As a HELP Committee member, he insists any future FDA commissioner must agree to these terms to secure his support.
The Trump administration has reportedly assured the completion of an exhaustive safety study on mifepristone by March 2027. Following this, the FDA is set to implement regulatory adjustments based on the study’s findings by September 2027. These changes will be applicable to both branded and generic versions of mifepristone.
The federal appeals court recently halted the mailing of abortion pills, affecting nationwide distribution.
Senator Hawley’s office highlighted that the forthcoming study will examine data from Medicaid and commercial providers, covering periods before and after changes made by the Biden administration to remove in-person dispensing requirements.
Since 2023, the federal oversight of mifepristone has faced increasing criticism after the Biden administration rescinded mandates for in-person doctor consultations and dispensing of the medication. The FDA has delayed its review multiple times despite previous commitments to share a study by 2025. Critics express concern that essential data is being overlooked.
Dr. Overton, in her Senate committee confirmation questionnaire, noted the FDA’s intention to finish the review efficiently with available data and qualified experts. She ensured making the scientific findings public as extensively as allowed by law. “If confirmed,” Overton stated, “I would support finalizing this work swiftly while ensuring the scientific review’s integrity.”
Senator Hawley, in March, called on Republicans to support legislation to ban mifepristone. “The evidence is clear,” he remarked, “Mifepristone is almost always fatal to the unborn child and also poses significant risks to women. Drug companies are profiting from its near-unregulated distribution, shielded largely from liability. Congress cannot continue ignoring these dangers.”